Recs

2

How Long Can This Pharma Gold Rush Last?

By | More Articles
February 10, 2013 | Comments (0)

In the following video, Brenton Flynn sits down with Fool.com analyst Brendan Byrnes to discuss a topic that's gathered considerable attention in recent years: orphan drug development. In particular, they discuss the reasons for this focus, as well as an interesting scenario in which a very small patient market has become saturated with options.

The future of MannKind?
While diabetes is far from an orphan disease, there's one company pursuing something extraordinary in the space. Will MannKind's disruptive technology revolutionize the way diabetes is treated around the world -- or will the FDA put the kibosh on this product before it even hits the market? In a new premium research report on MannKind, these complex issues are made crystal clear, in addition to showing you why to buy or sell the stock today. To find out more -- and get a full year of free updates -- click here to grab your copy today.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Brendan Byrnes and The Motley Fool have no position in any stocks mentioned. Brenton Flynn owns shares of Sarepta Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2246621, ~/Articles/ArticleHandler.aspx, 5/24/2013 8:55:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 15,294.50 -12.67 0.00%
S&P 500 1,650.51 -4.84 0.00%
NASD 3,459.42 -3.88 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/23/2013 4:00 PM
ISIS $20.64 Up +0.25 +0.00%
ISIS Pharmaceutica… CAPS Rating: **
AEGR $60.96 Up +2.71 +0.00%
Aegerion Pharmaceu… CAPS Rating: **
SRPT $37.94 Up +1.62 +0.00%
Sarepta Therapeuti… CAPS Rating: **
MRK $47.33 Up +0.62 +0.00%
Merck & Co., Inc. CAPS Rating: ****
ALXN $99.88 Down -0.69 +0.00%
Alexion Pharmaceut… CAPS Rating: **

Advertisement